EQL in-license seven products for Denmark

Report this content

EQL Pharma has today purchased seven (7) licenses, of which five (5) are exclusive, for products on the Danish market. The licenses already have marketing authorizations in Denmark. "These are niche generics that complement our portfolio well and fit into our strategy for the Nordic region and Denmark," says Christer Fåhraeus, CEO of EQL Pharma. The total turnover in the markets where these products compete is slightly more than 50mDKK (2020). All products are prescription-only and have between one and three active competitors, excluding EQL.

The sales start is expected in EQL Pharma’s first financial quarter 2021/22. “With this type of in-licensing, where the marketing authorization already exists, and we take over an existing stock, the market introduction takes place very rapidly and the competitive landscape is therefore well defined. In general, the price tag for in-licensing and purchasing of existing marketing authorizations are in the same order of magnitude as in-house development of niche products for the Nordic region”, says Christer Fåhraeus.

This disclosure contains information that EQL Pharma is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 15-03-2021 15:10 CET.

For further information, please contact:
Christer Fåhraeus
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e. medicines that are medically equivalent to originator medicines. The company currently has 17 niche generics (i.e. generics with little or no competition apart from the originator drug) approved in the Nordic markets. In addition to these, there exist a significant pipeline of additional niche generics for launch in 2021 and beyond. The business is currently entirely focused on prescription drugs. EQL Pharma AB conducts its operations in Lund, employs 10 people and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU, India and China, among others.


Documents & Links